Smith & Nephew Regulatory News (SN.)

Smith+Nephew announces non-executive changes to its Board

5 March 2020

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, is pleased to announce the appointment of Rick Medlock as a Non-Executive Director.

Rick will join the Board and Audit Committee on 9 April 2020 at the conclusion of the Annual General Meeting. It is envisaged that Rick will replace Robin Freestone as Chair of the Audit Committee later in the year. Robin will remain on the Board in his capacity as Senior Independent Director.

Rick is a Non-Executive Director of Sophos plc, where he also chairs the Audit Committee and Risk Committee. He has more than 30 years' experience of financial management in large international companies and was formerly Chief Financial Officer of Worldpay plc, Misys plc and Inmarsat plc.

Smith+Nephew also announces that Vinita Bali will be retiring as a Non-Executive Director at the end of 2020, on completion of 6 years' service, and that Baroness Virginia Bottomley will also be retiring as a Non-Executive Director at the Annual General Meeting in April 2021, following completion of 9 years' service.

Roberto Quarta, Chair of Smith+Nephew, said:

"I am delighted to welcome Rick Medlock to the Smith+Nephew Board. His extensive experience in both executive and non-executive finance leadership roles in global companies will strengthen our team.

"I would also like to take the opportunity of thanking both Vinita and Virginia for their outstanding service to the Company. We look forward to their continuing contribution to the work of the Board over the coming months."

-ENDS-

Enquiries

About Smith+Nephew

Smith+Nephew is a portfolio medical technology business that exists to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 17,500+ employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT. Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.1 billion in 2019. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.

◊ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

©2019 Smith+Nephew. All rights reserved.